Navigation Links
U of M study: Early treatment can reverse heart damage
Date:8/27/2007

MINNEAPOLIS/ST. PAUL (August 27, 2007) University of Minnesota researchers have discovered that treating people who have early cardiovascular abnormalities, but show no symptoms of cardiovascular disease, can slow progression and even reverse damage to the heart and blood vessels.

In a recent double-blind study, researchers enrolled 76 asymptomatic subjects with early markers for cardiovascular disease, based on a 10-factor scale called the Rasmussen Disease Score. During the first six months of the study, 38 subjects received a placebo, and the other 38 subjects took 160mg of Valsartan, a drug that blocks a hormone that is detrimental to the blood vessels and the heart. During the next six months, both groups took Valsartan.

Those who took the drug for the first six months significantly reduced their Rasmussen Disease Score compared with those who took the placebo. At the 12-month mark after both groups were taking the drug every patient showed better Rasmussen Disease Scores, effectively demonstrating that Valsartan can slow progression and even reverse early cardiovascular disease in asymptomatic high-risk patients. The findings of the study are published in the Aug. 28, 2007 issue of the Journal of American College of Cardiology.

Cardiovascular disease is the No. 1 killer in our society not only in the U.S. but in the rest of the world, said Daniel Duprez, M.D. professor of medicine, and the principal researcher. These patients have no symptoms, so most of them would have waited to seek treatment. Asymptomatic people are still treated based on risk factors, such as elevated blood pressure and cholesterol, but not on a personalized assessment of the presence of early cardiovascular disease. This is the first study that shows if you interfere early, you can cause regression of these cardiovascular abnormalities.

Most cardiovascular diseases are a result of a progressive problem that can be detected long before symptoms develop. Identifying individuals with early indications of disease can help doctors target the problem with lifestyle counseling and drug treatment to prevent future damage, Duprez said. Thats why the concept and validity of the Rasmussen Disease Score is a significant step toward the management of cardiovascular disease.

The Rasmussen Disease Score, developed by Jay N. Cohn, M.D. and director of the Universitys Rasmussen Center for Cardiovascular Disease Prevention, helps doctors identify early cardiovascular abnormalities that tend to lead to symptomatic cardiovascular disease.

The 10 tests in the Rasmussen Disease Score include: large and small artery elasticity; resting and treadmill exercise blood pressure; carotid artery initial-media thickness; retinal vascular photography; micro-albuminuria; electrocardiography; echocardiography; and plasma B-type natriuretic peptide blood levels.

This battery of tests together with a medical exam and counseling is performed in two hours in one location. The University of Minnesota Medical Center, Fairview is the only facility in the world that provides this screening process.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Counter study: cholesterol drugs no good in preventing colon cancer
2. A strategic study: Soy diet makes heart disease to worsen in male mice
3. Bird Flu Pandemic Study: Clerical & Support Staff May Stay At Home
4. Study: Older Pancreatic Cancer Surgery Survivors Live Long
5. New Study: Pine Bark Significantly Reduces Endometriosis
6. Gene linked to early puberty in girls
7. Cancer drugs in development nearly doubled since 1995
8. Nearly all asthma deaths preventable
9. Ductal lavage may detect early breast cancer
10. Doctors advice early anemia tests
11. Heart disease threat starts early in life for Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme ... Center for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) ... has compiled into a single volume a compelling argument that the disease does exist ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to ... new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 28, 2017 ... Research and Markets has announced the ... 2025" report to their offering. The global ... of USD 239.8 billion by 2025. The rising prevalence of lifestyle-induced ... over the forecast period. Advancements in recombinant molecular technologies and high ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 27, ... company developing proprietary therapeutics for the treatment of ... drug delivery platform, today announced that the U.S. ... initial review of the ropinirole implant Investigational New ... hold the initiation of the clinical study pending ...
Breaking Medicine Technology: